(redirected from Vioxx Gastrointestinal Outcomes Research)
VIGORVioxx Gastrointestinal Outcomes Research
VIGORVegetarian Information Group of Rochester (Rochester, MN)
VIGORVolunteers in Government of Responsibility (New Orleans, LA)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
The controversy began more than 2 years ago, when results of the Vioxx Gastrointestinal Outcomes Research (VIGOR) trial comparing rofecoxib (50 mg) and naproxen (1,000 mg) demonstrated a 50% cumulative lower rate of serious upper gastrointestinal events such as major bleeding, perforation, and obstruction (0.5% vs.
In a press release, the FDA said it approved the modifications based on the results of the Vioxx Gastrointestinal Outcomes Research (VIGOR) study, a yearlong, prospective, randomized, double-blind study comparing about 4,000 patients with RA on 50 mg of Vioxx a day, twice the standard chronic dose, with about 4,000 patients on the standard 1,000 mg a day dose of naproxen.
In the Vioxx Gastrointestinal Outcomes Research (VIGOR) trial, 8,076 rheumatoid arthritis patients were randomized to rofecoxib 50 mg/day or naproxen 1,000 mg/day.